Payment overview · 2025
General Payments
$766.66
39 reported records · 21 companies
Healthcare provider profile · identity verified
Michael Paul Minning, MD
Allopathic & Osteopathic Physicians|Family Medicine · EDGEWOOD, KY · NPI 1013974419
Verified facts
What the public records show
CMS Open Payments records show Michael Paul Minning, MD received $766.66 in general payments during 2025 across 39 reported records.
Novo Nordisk Inc accounted for 13.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Paxlovid, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $101.64 | 13.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $88.16 | 11.5% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.09 | 6.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.77 | 6.1% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $45.27 | 5.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $42.18 | 5.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $38.65 | 5.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.81 | 4.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.40 | 4.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.60 | 4.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.45 | 4.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.17 | 4.2% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $28.06 | 3.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.39 | 3.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $26.15 | 3.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $21.07 | 2.8% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $18.67 | 2.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.04 | 2.4% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $17.07 | 2.2% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $15.12 | 2.0% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $14.90 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $766.66 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.33 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $64.33 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $52.77 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.77 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $45.27 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $43.60 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $42.18 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $38.65 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.31 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $36.81 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $35.39 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $35.39 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.60 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $32.17 | 2 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $28.06 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.39 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $26.15 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 15 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
87 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 373 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 261 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 203 | 64 |
| Losartan Potassium | Losartan Potassium | 183 | 59 |
| Omeprazole | Omeprazole | 166 | 49 |
| Simvastatin | Simvastatin | 166 | 47 |
| Metformin Hcl Er | Metformin Hcl | 163 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 161 | 51 |
| Gabapentin | Gabapentin | 152 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 147 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 140 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 43 |
| Lisinopril | Lisinopril | 133 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 36 |
| Lorazepam | Lorazepam | 123 | 25 |
| Montelukast Sodium | Montelukast Sodium | 120 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 38 |
| Allopurinol | Allopurinol | 106 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 18 |
| Trazodone Hcl | Trazodone Hcl | 93 | 22 |
| Meloxicam | Meloxicam | 91 | 28 |
| Tramadol Hcl | Tramadol Hcl | 91 | 21 |
| Eliquis | Apixaban | 87 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 24 |
| Metformin Hcl | Metformin Hcl | 72 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 72 | 13 |
| Alprazolam | Alprazolam | 70 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 19 |
| Potassium Chloride | Potassium Chloride | 64 | 22 |
| Diazepam | Diazepam | 62 | 12 |
| Methylprednisolone | Methylprednisolone | 62 | 57 |
| Carvedilol | Carvedilol | 60 | 17 |
| Glimepiride | Glimepiride | 60 | 17 |
| Furosemide | Furosemide | 58 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 17 |
| Temazepam | Temazepam | 53 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 48 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 13 |
| Bumetanide | Bumetanide | 44 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 13 |
| Alendronate Sodium | Alendronate Sodium | 43 | 11 |
| Valsartan | Valsartan | 43 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 15 |
| Celecoxib | Celecoxib | 40 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 17 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 38 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 36 | suppressed |
| Finasteride | Finasteride | 35 | 11 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Famotidine | Famotidine | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | 11 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 11 |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 16 |
| Midodrine Hcl | Midodrine Hcl | 31 | suppressed |
| Azithromycin | Azithromycin | 29 | 27 |
| Cefuroxime | Cefuroxime Axetil | 29 | 22 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | 11 |
| Atenolol | Atenolol | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Nystatin | Nystatin | 27 | 11 |
| Risperidone | Risperidone | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Prednisone | Prednisone | 25 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 16 |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 20 |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 14 |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $766.66 · 39 records | Novo Nordisk Inc | ACCRUFER, Auvelity, CAPLYTA, Cologuard Collection Kit, DAYBUE, Dexcom G6 Transmitter, Doc Band, Dyanavel XR, EVENITY, JARDIANCE, JATENZO, Kerendia, MOUNJARO, OFEV, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, REXULTI, Rybelsus, TRINTELLIX, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, XYOSTED, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error